E
PTCT icon

Ergoteles’s PTC Therapeutics PTCT Stock Holding History

Ergoteles’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-42,389
Closed -$1.72M – 645
2023
Q2 		$1.72M Buy
42,389
+26,945
+174% +$1.32M 0.08% 311
2023
Q1 		$748K Sell
15,444
-26,899
-64% -$1.23M 0.03% 602
2022
Q4 		$1.62M Buy
42,343
+10,572
+33% +$439K 0.06% 326
2022
Q3 		$1.59M Buy
31,771
+6,930
+28% +$340K 0.06% 338
2022
Q2 		$995K Buy
24,841
+5,201
+26% +$182K 0.03% 544
2022
Q1 		$733K Sell
19,640
-9,620
-33% -$371K 0.03% 531
2021
Q4 		$1.17M Buy
+29,260
New +$1.12M 0.05% 378

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ergoteles's PTCT Position: Q3 2023 in Review

Ergoteles sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 42,389 shares — an estimated $1.72M sold.

Ergoteles first reported a position in PTCT in Q4 2021 and held it in 7 quarters. The position peaked at $1.72M in Q2 2023. 179 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

  • Ergoteles reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 42,389 PTC Therapeutics shares in Q3 2023, an estimated $1.72M.
  • Ergoteles first reported a position in PTC Therapeutics in Q4 2021 and held it in 7 quarters.
  • Ergoteles's PTC Therapeutics position peaked at $1.72M in Q2 2023.
  • 179 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.